Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | PRKCA | P17252 | 2/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29133986 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL17003748 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL611849 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL1340807 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL9503022 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL136431 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL9055250 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL440983 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL571428 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL29061395 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055374-A | Lipid compounds and compositions for tissue-specific delivery of active substances | 韩国生命工学研究院 | 2026-05-15 | — | — | CN | claimed |
| EP-4712950-A2 | IONIZABLE AMINE LIPIDS | Intellia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260077038-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2026-03-19 | — | — | US | claimed |
| US-20260069684-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2026-03-12 | — | — | US | claimed |
| EP-4661843-A2 | MULTI-FUNCTIONAL LIPID NANOPARTICLES AND USES THEREOF | University of Tennessee Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| US-20250319035-A1 | CATIONIC LIPID NANOPARTICLE HAVING HIGH TRANSFECTION EFFICIENCY AND PREPARATION METHOD THEREFOR | TONG, Shuwen (CN) | 2025-10-16 | — | — | US | claimed |
| CN-120078734-A | Lipid nanoparticle for delivering nucleic acid and preparation method and application thereof | 康希诺(上海)生物研发有限公司 | 2025-06-03 | — | — | CN | claimed |
| WO-2025083657-A1 | LIPID COMPOUND AND COMPOSITION FOR TISSUE-SPECIFIC DELIVERY OF ACTIVE SUBSTANCE | 한국생명공학연구원 | 2025-04-24 | — | — | WO | claimed |
| WO-2024243031-A2 | IONIZABLE AMINE LIPIDS | INTELLIA THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | WO | claimed |
| US-20240325525-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2024-10-03 | — | — | US | claimed |
| CN-118078752-A | Lipid composition for gene editing agent delivery and uses thereof | 北京启辰生生物科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-118064466-A | Polynucleotide for coding recombinant interleukin 12 and application thereof | 北京启辰生生物科技有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-118059222-A | Lyophilized preparation of mRNA lipid nanoparticle of 2019-nCoV S protein | 北京启辰生生物科技有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-118059059-A | Freeze-dried preparation of lipid nano particles | 北京启辰生生物科技有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-118021754-A | Needleless injector and lipid nanoparticle delivery system | 北京启辰生生物科技有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117624381-A | Therapeutic HPV mRNA vaccine and application thereof | 启辰生生物科技(珠海)有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-117534585-A | Novel ionizable cationic lipid compound, and preparation method and application thereof | 国家纳米科学中心 | 2024-02-09 | — | — | CN | claimed |
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2023-11-30 | — | — | US | claimed |
| WO-2023208076-A1 | CATIONIC LIPID NANOPARTICLE HAVING HIGH TRANSFECTION EFFICIENCY AND PREPARATION METHOD THEREFOR | 北京多纳医药科技有限公司 | 2023-11-02 | — | — | WO | claimed |
| EP-0655907-B1 | USE OF DIACYLOLYCEROLS FOR INCREASING THE MELANIN CONTENT IN MELANOCYTES | UNIV BOSTON (US) | 1999-04-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069684-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | PHOSPHO1, PLTP, SGMS1 | MAPT 4170/4885MAPK1 1439/4885LMNA 39/4885 |
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | PHOSPHO1, PTDSS1, PTDSS2 | MAPT 4135/4885MAPK1 1840/4885LMNA 136/4885 |
| US-20260077038-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | PHOSPHO1, LNPK, SGMS2 | MAPT 3597/4885MAPK1 1945/4885LMNA 153/4885 |
| US-20250319035-A1 | CATIONIC LIPID NANOPARTICLE HAVING HIGH TRANSFECTION EFFICIENCY AND PREPARATION METHOD THEREFOR | CETP, NPC1L1, LIPA | MAPT 1542/4885MAPK1 2115/4885LMNA 589/4885 |
| US-20240325525-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | PHOSPHO1, PTDSS1, PTDSS2 | MAPT 4135/4885MAPK1 1840/4885LMNA 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.